MAZE compared with ERAS: revenue, margins and what each company keeps, and the suppliers and customers both name

MAZEMaze Therapeutics, Inc.

Mkt capRevenueRevenue

ERASErasca, Inc.

Mkt capRevenueRevenue

Compare

MAZEMaze Therapeutics, Inc.

ERASErasca, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MAZE 4

NBIXNeurocrine Biosciencescustomer

—Shionogiunlistedcustomer

—Trace Neuroscienceunlistedcustomer

—Alloy Therapeuticsunlistedcustomer

Shared 0

No shared counterparties.

Only ERAS 5

—Emerge Life Sciences, Pteunlistedsupplier

—Guangzhou Joyo Pharmatechunlistedsupplier

—Medshine Discoveryunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—Novartis Pharmaunlistedsupplier

1 more · ERAS chain ›

MAZEMaze Therapeutics, Inc.

29.88▼−5.08%

Mkt cap$1.9BRevenue$20MQ1 FY26

ERASErasca, Inc.

13.88▼−3.27%

Regular sessionNov 2 '26

Mkt cap$5.0BRevenue—

Compare

Regular sessionNov 2 '26

MAZEMaze Therapeutics, Inc.

ERASErasca, Inc.

29.88▼−5.08%

Price

13.88▼−3.27%

$1.9B

Mkt cap

$5.0B

Q1 FY26$20M

Revenue

—

MAZE29.88▼−5.08%vsERAS13.88▼−3.27%Regular sessionNov 2 '26